Clinical Trial 7245

Hoover, AL 35216

Study Summary:

The primary objective of this study is to evaluate the effect of TAK-875 25, 50, 75, 100, and 150 mg QD on glycemic control over a 12-week treatment period in subjects with T2DM who are inadequately controlled by diet and exercise or a stable dose of metformin.

Qualified Participants Must:

• Be 18 to 80 years of age
• Have a history of Type 2 Diabetes without the chronic use (defined as >7 days) of antidiabetic therapy within 8 weeks prior to screening
• Have at least an 8-week documented history of a diet and exercise plan at screening OR
• Have a history of Type 2 Diabetes and be stable on at least 1500 mg per day or the respective (individually) maximal tolerated dose of metformin as monotherapy for at least 2 months prior to screening

Qualified Participants May Receive:

Subjects will be trained in self monitoring and documenting blood glucose levels. All subjects will be trained in recognition of hypoglycemia. Subjects will receive all clinic visits and medicines at no charge and reimbursement is available for time and travel.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.